Reliance Global Group, Inc 10-Q/A for FY2022 Q2
Reliance Global Group, Inc. (XGPU)
About this 10-Q/A
Reliance Global Group, Inc filed this 10-Q/A on May 18, 2023, covering the quarter ended June 30, 2022 (FY2022 Q2).
Headline figures
Quarter ended June 30, 2022, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $4.21M
- up 92.0% from $2.19M a year earlier
- Net income
- $10.5M
- compared with a net loss of $1.28M a year earlier
- Diluted EPS
- $8.61
- compared with -$1.75 a year earlier
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Amendment No. 1)
For
the quarterly period ended
or
For the transition period from _____ to _____
Commission
File Number:
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization)
I.R.S. Employer Identification Number
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code)
N/A
(Former name, former address, and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The
| ||||
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer ☐ | Accelerated filer ☐ | |
| Smaller
reporting company | ||
| Emerging
growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Act).
Yes
☐
At August 15, 2022 the registrant had shares of common stock, par value $0.086 per share, outstanding (after giving effect to the 1-for-15 reverse stock split that became effective on February 23, 2023).
EXPLANATORY NOTE
| (i) | reflect the restatement of earnings per share (“EPS”) information (the “Restatement”) in the condensed consolidated statements of operations for the three and six months ended June 30, 2022; |
| (ii) | insert additional disclosure relating to the Restatement to Note 1; |
| (iii) | replace Note 7 from the Original Form 10-Q in its entirety as a result of the Restatement; |
| (iv) | revise share and per share information throughout the Form 10-Q/A to give effect to the 1-for-15 reverse stock split that became effective on February 23, 2023 (the “Reverse Split”); |
| (v) | revise Part I, Item 4 to indicate that the Company’s disclosure controls and procedures were not effective as of June 30, 2022; |
| (vi) | replace the exhibit index contained in Item 6 in its entirety; |
| (vii) | provide current dated certifications; |
| (viii) | correct certain immaterial errors on the cover sheet to the Form 10-Q/A. |
The Restatement is due to the Company performing an evaluation of its accounting in connection with the calculation of its basic and diluted EPS for the three and six months ended June 30, 2022, and identification of errors in such calculations. On May 12, 2023, management concluded its evaluation and determined that the identified errors require the filing of Amendment No. 1, as further discussed in Notes 1 and 7 to the unaudited condensed consolidated financial statements included in this Form 10-Q/A.
The following items have been amended in this Amendment No. 1:
| ● | Part I — Item 1. Financial Statements | |
| ● | Part I – Item 4. Controls and Procedures | |
| ● | Part II – Item 6. Exhibits |
Except as described above, no other changes have been made to the Original Form 10-Q, and Amendment No. 1 does not modify, amend or update in any way revenue, expenses, net income (loss), or any of the financial or other information contained in the Original Form 10-Q. Amendment No. 1 does not reflect events that may have occurred subsequent to the filing date of the Original Form 10-Q other than adjusting, in the Items amended herein, common stock share and price per share information for the 1-for-15 reverse stock split that became effective February 23, 2023.
TABLE OF CONTENTS
| PART I | |
| Item 1. Financial Statements | 1 |
| Item 4. Controls and Procedures | 20 |
| PART II | |
| Item 6. Exhibits | 20 |
| Signatures | 21 |
PART I
Item 1. Financial Statements
Reliance Global Group, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(Unaudited)
June 30, 2022 | December 31, 2021 | |||||||
June 30, 2022 | December 31, 2021 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash | $ | $ | ||||||
| Restricted cash | ||||||||
| Accounts receivable | ||||||||
| Accounts receivable, related parties | ||||||||
| Prepaid expense and other current assets | ||||||||
| Total current assets | ||||||||
| Property and equipment, net | ||||||||
| Right-of-use assets | ||||||||
| Investment in NSURE, Inc. | ||||||||
| Intangibles, net | ||||||||
| Goodwill | ||||||||
| Other non-current assets | ||||||||
| Total assets | $ | $ | ||||||
| Liabilities and stockholders’ equity (deficit) | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and other accrued liabilities | $ | $ | ||||||
| Chargeback reserve | ||||||||
| Other payables | ||||||||
| Short term Financing Agreements | ||||||||
| Current portion of long-term debt | ||||||||
| Current portion of leases payable | ||||||||
| Earn-out liability, current portion | ||||||||
| Warrant commitment | ||||||||
| Total current liabilities | ||||||||
| Loans payable, related parties, less current portion | ||||||||
| Long term debt, less current portion | ||||||||
| Leases payable, less current portion | ||||||||
| Earn-out liability, less current portion | ||||||||
| Warrant liabilities | ||||||||
| Total liabilities | ||||||||
| Stockholders’ equity (deficit): | ||||||||
| Preferred stock, $ par value; shares authorized and and issued and outstanding as of June 30, 2022 and December 31, 2021, respectively | ||||||||
| Common stock, $ par value; shares authorized and and issued and outstanding as of June 30, 2022 and December 31, 2021, respectively | ||||||||
| Additional paid-in capital | ||||||||
| Stock subscription receivable | ( | ) | ||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total stockholders’ equity (deficit) | ( | ) | ||||||
| Total liabilities and stockholders’ equity (deficit) | $ | $ | ||||||
The accompanying notes are an integral part of these condensed consolidated financial statements
| 1 |
Reliance Global Group, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
(Unaudited)
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
Three months ended June 30, | Six months ended June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Revenue | ||||||||||||||||
| Commission income | $ | $ | $ | $ | ||||||||||||
| Total revenue | ||||||||||||||||
| Operating expenses | ||||||||||||||||
| Commission expense | $ | $ | $ | $ | ||||||||||||
| Salaries and wages | ||||||||||||||||
| General and administrative expenses | ||||||||||||||||
| Marketing and advertising | ||||||||||||||||
| Depreciation and amortization | ||||||||||||||||
| Total operating expenses | ||||||||||||||||
| Loss from operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other income (expense) | ||||||||||||||||
| Other expense, net | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Recognition and change in fair value of warrant liabilities | ||||||||||||||||
| Total other income (expense) | ( | ) | ( | ) | ||||||||||||
| Net income (loss) | $ | $ | ( | ) | $ | $ | ( | ) | ||||||||
| Basic earnings (loss) per share | $ | $ | ( | ) | $ | $ | ( | ) | ||||||||
| Diluted earnings (loss) per share | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||
| Weighted average number of shares outstanding - Basic | ||||||||||||||||
| Weighted average number of shares outstanding - Diluted | ||||||||||||||||
The accompanying notes are an integral part of these condensed consolidated financial statements
| 2 |
Reliance Global Group, Inc. and Subsidiaries
Condensed Consolidated Statements of Stockholders’ Equity (Deficit)
(Unaudited)
| Shares | Amount | Shares | Amount | Shares | Amount | capital | Receivable | Deficit | Total | |||||||||||||||||||||||||||||||
| Reliance Global Group, Inc. | ||||||||||||||||||||||||||||||||||||||||
| Preferred stock | Common stock | Common stock issuable | Additional paid-in | Subscription | Accumulated | |||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | capital | Receivable | Deficit | Total | |||||||||||||||||||||||||||||||
| Balance, December 31, 2021 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||||||
| Share based compensation | - | - | - | |||||||||||||||||||||||||||||||||||||
| Shares issued due to private placement | - | ( | ) | |||||||||||||||||||||||||||||||||||||
| Shares issued pursuant to acquisition of Medigap | - | - | ||||||||||||||||||||||||||||||||||||||
| Exercise of Series A warrants | - | - | ||||||||||||||||||||||||||||||||||||||
| Issuance of prefunded Series C Warrants in exchange for common shares | - | ( | ) | ( | ) | - | ||||||||||||||||||||||||||||||||||
| Shares issued for vested stock awards | - | - | ( | ) | ||||||||||||||||||||||||||||||||||||
| Net Income | - | - | - | |||||||||||||||||||||||||||||||||||||
| Balance, March 31, 2022 | $ | $ | $ | $ | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||||||||||
| Share based compensation | - | - | - | |||||||||||||||||||||||||||||||||||||
| Exercise of Series C warrants into common shares | - | - | ( | ) | ||||||||||||||||||||||||||||||||||||
| Net Income | - | - | - | |||||||||||||||||||||||||||||||||||||
| Balance, June 30, 2022 | $ | $ | $ | $ | $ | $ | ( | ) | $ | |||||||||||||||||||||||||||||||
The accompanying notes are an integral part of these condensed consolidated financial statements
| 3 |
Reliance Global Group, Inc. and Subsidiaries
Condensed Consolidated Statements of Stockholders’ Equity (Deficit)
(Unaudited)
| Shares | Amount | Shares | Amount | Shares | Amount | capital | Deficit | Total | |||||||||||||||||||||||||||||
| Reliance Global Group, Inc. | |||||||||||||||||||||||||||||||||||||
| Preferred stock | Common stock | Common stock issuable | Additional paid-in | Accumulated | |||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | capital | Deficit | Total | |||||||||||||||||||||||||||||
| Balance, December 31, 2020 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||||||
| Share based compensation | - | - | - | ||||||||||||||||||||||||||||||||||
| Shares issued for services | - | - | |||||||||||||||||||||||||||||||||||
| Shares issued due to public offering, net of offering costs of $ | - | - | |||||||||||||||||||||||||||||||||||
| Over-allotment shares from offering, net of offering costs of $ | - | - | |||||||||||||||||||||||||||||||||||
| Warrants sold during public offering at quoted price | - | - | - | ||||||||||||||||||||||||||||||||||
| Shares issued due to conversion of preferred stock | ( | ) | ( | ) | - | ||||||||||||||||||||||||||||||||
| Shares issued due to conversion of debt | - | - | |||||||||||||||||||||||||||||||||||
| Rounding shares related to initial public offering | - | ||||||||||||||||||||||||||||||||||||
| Shares issued pursuant to software purchase | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
| Net loss | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||
| Balance, March 31, 2021 | $ | $ | $ | $ | $ | ( | ) | $ | |||||||||||||||||||||||||||||
| Share based compensation | - | - | - | ||||||||||||||||||||||||||||||||||
| Rounding shares related to initial public offering | - | - | |||||||||||||||||||||||||||||||||||
| Shares issued pursuant to acquisition of Kush | - | - | |||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||
| Balance, June 30, 2021 | $ | $ | $ | $ | $ | ( | ) | $ | |||||||||||||||||||||||||||||
The accompanying notes are an integral part of these condensed consolidated financial statements
| 4 |
Reliance Global Group, Inc. and Subsidiaries and Predecessor
Condensed Consolidated Statements of Cash Flows
(Unaudited)
| 2022 | 2021 | |||||||
| Six months ended June 30, | ||||||||
| 2022 | 2021 | |||||||
| Cash flows from operating activities: | ||||||||
| Net income (loss) | $ | $ | ( | ) | ||||
| Adjustment to reconcile net income (loss) to net cash used in operating activities: | ||||||||
| Depreciation and amortization | ||||||||
| Amortization of debt issuance costs and accretion of debt discount | ||||||||
| Non-cash lease expense | ||||||||
| Stock compensation expense | ||||||||
| Earn-out fair value and write-off adjustments | ||||||||
| Recognition and change in fair value of warrant liabilities | ( | ) | ||||||
| Change in operating assets and liabilities: | ||||||||
| Accounts payables and other accrued liabilities | ( | ) | ( | ) | ||||
| Accounts receivable | ||||||||
| Accounts receivable, related parties | ( | ) | ( | ) | ||||
| Other payables | ||||||||
| Charge back reserve | ||||||||
| Other non-current assets | ( | ) | ( | ) | ||||
| Prepaid expense and other current assets | ( | ) | ||||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| Cash flows from investing activities: | ||||||||
| Purchase of property and equipment | ( | ) | ||||||
| Business acquisitions, net of cash acquired | ( | ) | ( | ) | ||||
| Purchase of intangibles | ( | ) | ( | ) | ||||
| Net cash used in investing activities | ( | ) | ( | ) | ||||
| Cash flows from financing activities: | ||||||||
| Principal repayments of debt | ( | ) | ( | ) | ||||
| Proceeds from loan for business acquisition | ||||||||
| Payment of debt issuance costs | ( | ) | ||||||
| Payments on earn-out liabilities | ( | ) | ||||||
| Proceeds from loans payable, related parties | ||||||||
| Payments of loans payable, related parties | ( | ) | ( | ) | ||||
| Proceeds from exercise of warrants into common stock | ||||||||
| Repayments on short-term financing | ( | ) | ||||||
| Net proceeds from private placement issuance of shares and warrants | ||||||||
| Issuance of common stock | ||||||||
| Net cash provided by financing activities | ||||||||
| Net (decrease) increase in cash and restricted cash | ( | ) | ||||||
| Cash and restricted cash at beginning of period | ||||||||
| Cash and restricted cash at end of period | $ | $ | ||||||
| Supplemental disclosure of cash and non-cash investing and financing transactions: | ||||||||
| Issuance of Series D Warrants | $ | $ | ||||||
| Issuance of placement agent warrants | $ | $ | ||||||
| Prepaid insurance acquired through short-term financing | $ | $ | ||||||
| Conversion of preferred stock into common stock | $ | $ | ||||||
| Cash paid for interest | $ | $ | ||||||
| Conversion of debt into equity | $ | $ | ||||||
| Common stock issued pursuant to acquisition | $ | $ | ||||||
| Common stock issued in lieu of services | $ | $ | ||||||
| Issuance of common stock pursuant to the purchase of software | $ | $ | ||||||
| Acquisition of business deferred purchase price | $ | $ | ||||||
| Lease assets acquired in exchange for lease liabilities | $ | $ | ||||||
The accompanying notes are an integral part of these condensed consolidated financial statements
| 5 |
Reliance Global Group, Inc. and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
NOTE 1. SUMMARY OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES
Reliance Global Group, Inc., formerly known as Ethos Media Network, Inc. (“RELI”, “Reliance”, or the “Company”) incorporated in Florida on August 2, 2013.
Basis of Presentation and Principles of Consolidation
The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions for Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of recurring accruals) necessary for a fair presentation have been included. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto, set forth in the Company’s annual report on Form 10-K for the year ended December 31, 2021.
The accompanying unaudited condensed consolidated financial statements include the accounts of Reliance Global Group, Inc. and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.
Restatement of Previously Issued Financial Statements
Subsequent to the Company’s filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, with the Securities and Exchange Commission on August 15, 2022, the Company performed an evaluation of its accounting in connection with the calculations of its basic Earnings Per Share (“EPS”) and diluted EPS for the three and six month periods ended June 30, 2022, which concluded on May 12, 2023, and identified errors in such calculations. The errors resulted from improper application of sequencing rules, a miscalculation of the numerator used in the determination of diluted EPS, and a miscalculation of the denominator used in the determination of weighted average shares outstanding for both basic EPS and diluted EPS, and the Company determined that the errors required adjustments of the previously issued financial statements for the three and six months ended June 30, 2022. Accordingly, the Company restates its consolidated financial statements for the identified periods in this Form 10-Q/A as outlined further below and in Note 7 Earnings (Loss) Per Share.
The following table sets forth the effects of the adjustments on affected items within the Company’s previously reported consolidated statements of operations for the three months ended June 30, 2022, and includes an increase to basic earnings per share in the amount of $, an increase to diluted earnings per share in the amount of $, a decrease to weighted average number of shares outstanding – basic of shares, and a decrease to weighted average number of shares outstanding - diluted of shares.
SCHEDULE OF PREVIOUSLY REPORTED CONSOLIDATED STATEMENTS OF OPERATIONS
| Three Months Ended June 30, 2022 | ||||||||||||
| As Reported | Adjustment | As Corrected | ||||||||||
| Basic earnings (loss) per share | ||||||||||||
| Diluted earnings (loss) per share | ( | ) | ||||||||||
| Weighted average number of shares outstanding – Basic | ( | ) | ||||||||||
| Weighted average number of shares outstanding - Diluted | ( | ) | ||||||||||
The following table sets forth the effects of the adjustments on affected items within the Company’s previously reported consolidated statements of operations for the six months ended June 30, 2022, and includes an increase to basic earnings per share in the amount of $, an increase to diluted loss per share in the amount of $, a decrease to weighted average number of shares outstanding – basic of shares, and a decrease to weighted average number of shares outstanding - diluted of shares.
| Six Months Ended June 30, 2022 | ||||||||||||
| As Reported | Adjustment | As Corrected | ||||||||||
| Basic earnings (loss) per share | ||||||||||||
| Diluted earnings (loss) per share | ( | ) | ( | ) | ( | ) | ||||||
| Weighted average number of shares outstanding – Basic | ( | ) | ||||||||||
| Weighted average number of shares outstanding - Diluted | ( | ) | ||||||||||
Additionally, please refer to Note 7. Earnings (Loss) Per Share, where the Company has corrected and replaced that Note in its entirety.
Liquidity
As
of June 30, 2022, the Company’s reported cash and restricted cash aggregated balance was approximately $
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.
| 6 |
Cash and Restricted Cash
Cash and restricted cash reported on our Condensed Consolidated Balance Sheets are reconciled to the total shown on our Condensed Consolidated Statements of Cash Flows as follows:
SCHEDULE OF RESTRICTED CASH IN STATEMENT OF CASH FLOW
| June 30, 2022 | June 30, 2021 | |||||||
| Cash | $ | $ | ||||||
| Restricted cash | ||||||||
| Total cash and restricted cash | $ | $ | ||||||
Fair Value of Financial Instruments
Level 1 — Observable inputs reflecting quoted prices (unadjusted) in active markets for identical assets and liabilities;
Level 2 — Inputs other than quoted prices in active markets for identical assets and liabilities that are observable either directly or indirectly for substantially the full term of the asset or liability; and
Level 3 — Unobservable inputs for the asset or liability, which include management’s own assumption about the assumptions market participants would use in pricing the asset or liability, including assumptions about risk.
Warrant Liabilities: The Company re-measures fair value of its Level 3 warrant liabilities at the balance sheet date, using a binomial option pricing model. The following summarizes the significant unobservable inputs not adjusting for any reverse stock splits:
SCHEDULE OF FAIR VALUE OF WARRANT COMMITMENT
| June 30, 2022 | December 31, 2021 | |||||||
| Stock price | $ | $ | ||||||
| Volatility | % | % | ||||||
| Time to expiry | ||||||||
| Dividend yield | % | % | ||||||
| Risk free rate | % | % | ||||||
The following reconciles fair value of the liability classified warrants:
SCHEDULE OF RECONCILES WARRANT COMMITMENT
| Series B Warrant Commitment | Series B warrant liabilities | Placement agent warrants | Total | |||||||||||||
| Three and Six Months ended June 30, 2022 | ||||||||||||||||
| Series B Warrant Commitment | Series B warrant liabilities | Placement agent warrants | Total | |||||||||||||
| Beginning balance | $ | $ | $ | $ | ||||||||||||
| Initial recognition | ||||||||||||||||
| Unrealized (gain) loss | ( | ) | ( | ) | ( | ) | ||||||||||
| Warrants exercised or transferred | ( | ) | ( | ) | ||||||||||||
| Ending balance, March 31, 2022 | $ | $ | $ | $ | ||||||||||||
| Unrealized gain | ( | ) | ( | ) | ( | ) | ||||||||||
| Ending balance, June 30, 2022 | ||||||||||||||||
| Series B Warrant Commitment | Total | |||||||
| December 31, 2021 | ||||||||
| Series B Warrant Commitment | Total | |||||||
| Beginning balance | $ | $ | ||||||
| Initial recognition | ||||||||
| Unrealized gain | ||||||||
| Ending balance | $ | $ | ||||||
Earn-out liabilities: The Company generally values its Level 3 earn-out liabilities using the income valuation approach. Key valuation inputs include contingent payment arrangement terms, projected revenues and cash flows, rate of return, and probability assessments. The following table summarizes the significant unobservable inputs used in the fair value measurements:
SCHEDULE OF FAIR VALUE MEASUREMENTS
| June 30, 2022 | December 31, 2021 | |||||||
| Valuation technique | ||||||||
| Significant unobservable input | ||||||||
| 7 |
The Company values its Level 3 earn-out liability related to the Barra Acquisition using a Monte Carlo simulation in a risk-neutral framework (a special case of the Income Approach). The following summarizes the significant unobservable inputs:
SCHEDULE OF EARN OUT LIABILITY
| June 30, 2022 | ||||
| WACC Risk Premium: | % | |||
| Volatility | % | |||
| Credit Spread: | % | |||
| Payment Delay (days) | % | |||
| Risk free rate | ||||
| Discounting Convention: | ||||
| Number of Iterations | ||||
Undiscounted
remaining earn out payments are approximately $
SCHEDULE OF GAIN OR LOSSES RECOGNIZED FAIR VALUE
| June 30, 2022 | December 31, 2021 | |||||||
| Beginning balance – January 1 | $ | $ | ||||||
| Acquisitions and Settlements | ||||||||
| JP Kush Acquisition | ||||||||
| Barra Acquisition | ||||||||
| CCS Write-off | ( | ) | ||||||
| Altruis partial settlement | ( | ) | ( | ) | ||||
| Montana final settlement | ( | ) | ||||||
| Period adjustments: | ||||||||
| Fair value changes and accretion included in earnings* | ( | ) | ||||||
| Ending balance | $ | $ | ||||||
| Less: Current portion | ( | ) | ( | ) | ||||
| Ending balance, less current portion | ||||||||
| * |
Revenue Recognition
The following table disaggregates the Company’s revenue by line of business, showing commissions earned:
SCHEDULE OF DISAGGREGATION REVENUE
| Three Months ended June 30, 2022 | Medical/Life | Property and Casualty | Total | |||||||||
| Regular | ||||||||||||
| EBS | $ | $ | $ | |||||||||
| USBA | ||||||||||||
| CCS/UIS | ||||||||||||
| Montana | ||||||||||||
| Fortman | ||||||||||||
| Altruis | ||||||||||||
| Kush | ||||||||||||
| Medigap | ||||||||||||
| Barra | ||||||||||||
| $ | $ | $ | ||||||||||
| 8 |
| Six Months ended June 30, 2022 | Medical/Life | Property and Casualty | Total | |||||||||
| Regular | ||||||||||||
| EBS | $ | $ | $ | |||||||||
| USBA | ||||||||||||
| CCS/UIS | ||||||||||||
| Montana | ||||||||||||
| Fortman | ||||||||||||
| Altruis | ||||||||||||
| Kush | ||||||||||||
| Medigap | ||||||||||||
| Barra | ||||||||||||
| $ | $ | $ | ||||||||||
| Three Months ended June 30, 2021 | Medical/Life | Property and Casualty | Total | |||||||||
| Regular | ||||||||||||
| EBS | ||||||||||||
| USBA | ||||||||||||
| CCS/UIS | ||||||||||||
| Montana | ||||||||||||
| Fortman | ||||||||||||
| Altruis | ||||||||||||
| Kush | ||||||||||||
| $ | $ | $ | ||||||||||
| Six Months ended June 30, 2021 | Medical/Life | Property and Casualty | Total | |||||||||
| Regular | ||||||||||||
| EBS | $ | $ | $ | |||||||||
| USBA | ||||||||||||
| CCS/UIS | ||||||||||||
| Montana | ||||||||||||
| Fortman | ||||||||||||
| Altruis | ||||||||||||
| Kush | ||||||||||||
| $ | $ | $ | ||||||||||
The
following, are customers representing
SCHEDULE OF CONCENTRATIONS OF REVENUES
| Insurance Carrier | 2022 | 2021 | ||||||
For the three months ended June 30, | ||||||||
| Insurance Carrier | 2022 | 2021 | ||||||
| LTC Global | % | % | ||||||
| Priority Health | % | % | ||||||
| BlueCross BlueShield | % | % | ||||||
| 9 |
| Insurance Carrier | 2022 | 2021 | ||||||
For the six months ended June 30, | ||||||||
| Insurance Carrier | 2022 | 2021 | ||||||
| BlueCross BlueShield | % | % | ||||||
| Priority Health | % | % | ||||||
| LTC Global | % | % | ||||||
No
other single Customer accounted for more than
Income Taxes
The Company recorded no income tax expense for the three and six months ended June 30, 2022 and 2021 because the estimated annual effective tax rate was zero. In determining the estimated annual effective income tax rate, the Company analyzes various factors, including projections of the Company’s annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, the ability to use tax credits and net operating loss carry forwards, and available tax planning alternatives.
As of June 30, 2022 and December 31, 2021, the Company provided a full valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized.
Prior Period Adjustments
The Company identified certain immaterial adjustments impacting prior reporting periods. Specifically, the Company identified adjustments to correct certain asset, liability and equity accounts in relation to historical purchase price allocation accounting, historical accrued revenues and true ups of the common stock issuable account.
The Company assessed the materiality of the adjustments to prior period financial statements in accordance with Securities and Exchange Commission Staff Accounting Bulletin No. (SAB) 99, Materiality, and SAB 108, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements, and ASC 250, Accounting Changes and Error Corrections.
Accordingly, the Company’s comparative condensed consolidated financial statements and impacted notes have been revised from amounts previously reported to reflect these adjustments. The following table illustrates the impact on previously reported amounts and adjusted balances presented in the condensed consolidated financial statements for the period ended June 30, 2022.
SUMMARIZES THE CHANGES TO THE PREVIOUSLY ISSUED FINANCIAL INFORMATION
| Account | 12/31/2020 As reported | Adjustment | 12/31/2020 Adjusted | |||||||||
| Earn-out liability | ||||||||||||
| Goodwill | ( | ) | ||||||||||
| Common stock issuable | ( | ) | ||||||||||
| Additional paid-in-capital | ||||||||||||
| Accumulated Deficit | ( | ) | ( | ) | ||||||||
| Account | 3/31/2021 As reported | Adjustment | 3/31/2021 Adjusted | |||||||||
| Common stock issuable | ( | ) | ||||||||||
| Additional paid-in-capital | ||||||||||||
| Accumulated Deficit | ( | ) | ( | ) | ||||||||
| 10 |
Recently Issued Accounting Pronouncements
We do not expect any recently issued accounting pronouncements to have a material effect on our financial statements.
NOTE 2. STRATEGIC INVESTMENTS AND BUSINESS COMBINATIONS
Medigap Healthcare Insurance Company, LLC Transaction
On
January 10, 2022, pursuant to an asset purchase agreement, dated December 21, 2021, the Company completed the acquisition of all of the
assets of Medigap Healthcare Insurance Company, LLC (“Medigap”) for a purchase price of $
The acquisition of Medigap was accounted for as a business combination in accordance with the acquisition method pursuant to FASB Topic No. 805, Business Combination (ASC 805). Accordingly, the total purchase consideration was allocated to the assets acquired, and liabilities assumed based on their respective estimated fair values. The acquisition method of accounting requires, among other things, that assets acquired, and liabilities assumed, if any, in a business purchase combination be recognized at their fair values as of the acquisition date. The process for estimating the fair values of identifiable intangible assets and certain tangible assets requires the use of significant estimates and assumptions, including estimating future cash flows, developing appropriate discount rates, estimating the costs, and timing.
The preliminary allocation of the purchase price in connection with the acquisition of Medigap was calculated as follows:
SCHEDULE OF ALLOCATION OF PURCHASE PRICE
| Description | Fair Value | Weighted Average Useful Life (Years) | ||||||
| Property, plant and equipment | $ | |||||||
| Right-of-use asset | ||||||||
| Trade names | ||||||||
| Customer relationships | ||||||||
| Technology | ||||||||
| Backlog | ||||||||
| Chargeback reserve | ( | ) | ||||||
| Lease liability | ( | ) | ||||||
| Goodwill | ||||||||
| $ | ||||||||
Trade
name was measured at fair value using the relief-from-royalty method under the income approach. Significant inputs used to measure the
fair value include an estimate of projected revenue from the trade name, a pre-tax royalty rate of
Customer
relationships were measured at fair value using the multiple-period excess earnings method under the income approach. Significant inputs
used to measure the fair value include an estimate of projected revenue and costs associated with existing customers, and a discount
rate of
Technology
was measured at fair value using the cost replacement method of the cost approach. Significant inputs used to measure the fair value
include an estimate of cost to replace, an obsolescence rate of
| 11 |
The
value assigned to backlog acquired was estimated based upon the contractual nature of the backlog as of the acquisition date, using the
income approach to discount back to present value the cash flows attributable to the backlog, using a discount rate of
Goodwill
of $
The
approximate revenue and net profit or loss for the acquired business as a standalone entity per ASC 805 from January 10, 2022 to June
30, 2022 was $
Pro Forma Information
The results of operations of Medigap will be included in the Company’s consolidated financial statements as of the date of acquisition through the current period end. The following supplemental pro forma financial information approximate combined financial information assumes that the acquisition had occurred at the beginning of the six months ended June 30, 2022 and 2021:
SCHEDULE OF PRO FORMA INFORMATION RELATED TO ACQUISITION
| June 30, | June 30, | |||||||
| 2022 | 2021 | |||||||
| Revenue | $ | $ | ||||||
| Net Income (Loss) | $ | $ | ( | ) | ||||
| Earnings (Loss) per common share, basic | $ | $ | ) | |||||
| Earnings (Loss) per common share, diluted | $ | ) | $ | ) | ||||
Barra & Associates, LLC Transaction
On
April 26, 2022, the Company entered into an asset purchase agreement (the “APA”) with Barra & Associates, LLC (“Barra”)
pursuant to which the Company purchased all of the assets of Barra & Associates, LLC on April 26, 2022 for a purchase price in the
amount of $
The acquisition of Barra was accounted for as a business combination in accordance with the acquisition method pursuant to FASB Topic No. 805, Business Combination (ASC 805). Accordingly, the total purchase consideration was allocated to the assets acquired, and liabilities assumed based on their respective estimated fair values. The acquisition method of accounting requires, among other things, that assets acquired, and liabilities assumed, if any, in a business purchase combination be recognized at their fair values as of the acquisition date. The process for estimating the fair values of identifiable intangible assets and certain tangible assets requires the use of significant estimates and assumptions, including estimating future cash flows, developing appropriate discount rates, estimating the costs, and timing.
| 12 |
The preliminary allocation of the purchase price in connection with the acquisition of Barra was calculated as follows:
SCHEDULE OF ALLOCATION OF PURCHASE PRICE
| Description | Fair Value | Weighted Average Useful Life (Years) | ||||||
| Acquired accounts receivable | $ | |||||||
| Property, plant and equipment | ||||||||
| Right-of-use asset | ||||||||
| Trade names | ||||||||
| Customer relationships | ||||||||
| Agency relationships | ||||||||
| Developed technology | ||||||||
| Lease liability | ( | ) | ||||||
| Goodwill | ||||||||
| $ | ||||||||
Trade
name was measured at fair value using the relief-from-royalty method under the income approach. Significant inputs used to measure the
fair value include an estimate of projected revenue from the trade name, a pre-tax royalty rate of
Customer
and Agency relationships were measured at fair value using the multiple-period excess earnings method under the income approach. Significant
inputs used to measure the fair value include an estimate of projected revenue and costs associated with existing customers, and a discount
rate of
Developed
technology was measured at fair value using the cost replacement method of the cost approach. Significant inputs used to measure the
fair value include an estimate of cost to replace, an obsolescence rate of
Goodwill
of $
The
approximate revenue and net profit or loss for the acquired business as a standalone entity per ASC 805 from April 26, 2022 to June 30,
2022 was $
Pro Forma Information
The results of operations of Barra will be included in the Company’s consolidated financial statements as of the date of acquisition through the current period end. The following supplemental pro forma financial information approximate combined financial information assumes that the acquisition had occurred at the beginning of the six months ended June 30, 2022 and 2021:
SCHEDULE OF PRO FORMA INFORMATION RELATED TO ACQUISITION
| June 30, | June 30, | |||||||
| 2022 | 2021 | |||||||
| Revenue | $ | $ | ||||||
| Net Income (Loss) | $ | $ | ( | ) | ||||
| Earnings (Loss) per common share, basic | $ | $ | ( | ) | ||||
| Earnings (Loss) per common share, diluted | $ | ( | ) | $ | ( | ) | ||
| 13 |
NOTE 3. GOODWILL AND OTHER INTANGIBLE ASSETS
The
following table rolls forward the Company’s goodwill balance for the periods ending June 30, 2022 and December 31, 2021. As
discussed in Note 1 - Prior Period Adjustments, a $(
SCHEDULE OF IMPAIRMENT OF GOODWILL
| Goodwill | ||||
| December 31, 2020 | $ | |||
| Goodwill recognized in connection with Kush acquisition on May 1, 2021 | $ | |||
| December 31, 2021 | $ | |||
| Goodwill recognized in connection with Medigap acquisition on January 10, 2022 | $ | |||
| Goodwill recognized in connection with Barra acquisition on April 26, 2022 | ||||
| June 30, 2022 | $ | |||
The following table sets forth the major categories of the Company’s intangible assets and the weighted-average remaining amortization period as of June 30, 2022:
SCHEDULE OF INTANGIBLE ASSETS AND WEIGHTED-AVERAGE REMAINING AMORTIZATION PERIOD
| Weighted Average Remaining Amortization period (Years) | Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount | |||||||||||||
| Trade name and trademarks | $ | $ | ( | ) | $ | |||||||||||
| Internally developed software | ( | ) | ||||||||||||||
| Customer relationships | ( | ) | ||||||||||||||
| Purchased software | ( | ) | ||||||||||||||
| Video Production Assets | ( | ) | ||||||||||||||
| Non-competition agreements | ( | ) | ||||||||||||||
| Contracts Backlog | ( | ) | ||||||||||||||
| $ | $ | ( | ) | $ | ||||||||||||
The following table sets forth the major categories of the Company’s intangible assets and the weighted-average remaining amortization period as of December 31, 2021:
| Weighted Average Remaining Amortization period (Years) | Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount | |||||||||||||
| Trade name and trademarks | $ | $ | ( | ) | $ | |||||||||||
| Internally developed software | ( | ) | ||||||||||||||
| Customer relationships | ( | ) | ||||||||||||||
| Purchased software | ( | ) | ||||||||||||||
| Video Production Assets | ||||||||||||||||
| Non-competition agreements | ( | ) | ||||||||||||||
| $ | $ | ( | ) | $ | ||||||||||||
| 14 |
The following table reflects expected amortization expense as of June 30, 2022, for each of the following five years and thereafter:
SCHEDULE OF AMORTIZATION EXPENSE OF ACQUIRED INTANGIBLES ASSETS
| Years ending December 31, | Amortization Expense | |||
| 2022 (remainder of year) | $ | |||
| 2023 | ||||
| 2024 | ||||
| 2025 | ||||
| 2026 | ||||
| Thereafter | ||||
| Total | $ | |||
NOTE 4. LONG-TERM DEBT AND SHORT-TERM FINANCINGS
Long-Term Debt
The composition of the long-term debt follows:
SCHEDULE OF LONG TERM DEBT
June 30, 2022 | December 31, 2021 | |||||||
| Oak Street Funding LLC Term Loan for the acquisition of EBS and USBA, net of deferred financing costs of $ | $ | $ | ||||||
| Oak Street Funding LLC Senior Secured Amortizing Credit Facility for the acquisition of CCS, net of deferred financing costs of $ | ||||||||
| Oak Street Funding LLC Term Loan for the acquisition of SWMT, net of deferred financing costs of $ | ||||||||
| Oak Street Funding LLC Term Loan for the acquisition of FIS, net of deferred financing costs of $ | ||||||||
| Oak Street Funding LLC Term Loan for the acquisition of ABC, net of deferred financing costs of $ | ||||||||
| Oak Street Funding LLC Term Loan for the acquisition of Barra, net of deferred financing costs of $ | ||||||||
| Less: current portion | ( | ) | ( | ) | ||||
| Long-term debt | $ | $ | ||||||
Oak Street Funding LLC – Term Loans and Credit Facilities
SCHEDULE OF CUMULATIVE MATURITIES OF LONG-TERM LOANS AND CREDIT FACILITIES
| Fiscal year ending December 31, | Maturities of Long-Term Debt | |||
| 2022 (remainder of year) | $ | |||
| 2023 | ||||
| 2024 | ||||
| 2025 | ||||
| 2026 | ||||
| Thereafter | ||||
| Total | ||||
| Less: debt issuance costs | ( | ) | ||
| Total | $ | |||
| 15 |
Short-Term Financings
The
Company financed certain annual insurance premiums through the use of two short-term notes, payable in nine and ten equal monthly
installments of $
NOTE 5. WARRANT LIABILITIES
Series B Warrants
On
December 22, 2021, the Company entered into a securities purchase agreement with several institutional buyers for the purchase and sale
of (i) warrants to purchase an aggregate of up to
By
entering into the Private Placement on December 22, 2021, the Company entered into a commitment to issue the Common Shares, Preferred
Shares and Series B Warrants on the Initial Closing Date for a fixed price and exercise price, as applicable. The commitment to issue
Series B Warrants (the “Warrant Commitment”) represents a derivative financial instrument, other than an outstanding share,
that, at inception, has both of the following characteristics: (i) embodies a conditional obligation indexed to the Company’s equity.
The Company classified the commitment to issue the warrants as a derivative liability because it represents a written option that does
not qualify for equity accounting The Company initially measured the derivative liability at its fair value and will subsequently remeasure
the derivative liability, at fair value with changes in fair value recognized in earnings. An option pricing model was utilized to calculate
the fair value of the Warrant Commitment. The Company initially recorded $
Placement Agent Warrants
In
connection with the Private Placement, the Company issued
| 16 |
NOTE 6. EQUITY
Preferred Stock
The Company has been authorized to issue shares of $ par value Preferred Stock. The Board of Directors is expressly vested with the authority to divide any or all of the Preferred Stock into series and to fix and determine the relative rights and preferences of the shares of each series so established, within certain guidelines established in the Articles of Incorporation.
In January 2022, the Company issued shares of its newly designated Series B convertible preferred stock through the Private Placement for the purpose of raising capital. These shares remain issued and outstanding as of June 30, 2022.
The Series B convertible preferred stock has no voting rights and initially each share of Series B convertible preferred stock may be converted into shares of the Company’s common stock. The holders of the Series B convertible preferred stock are not entitled to receive any dividends other than any dividends paid on account of the common stock. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders shall be entitled to receive out of the assets, whether capital or surplus, of the Company the same amount that a holder of common stock would receive if the Preferred Stock were fully converted (disregarding for such purposes any conversion limitations hereunder) to common stock which amounts shall be paid pari passu with all holders of common stock.
Common Stock
The Company has been authorized to issue shares of common stock, $par value. Each share of issued and outstanding common stock shall entitle the holder thereof to fully participate in all shareholder meetings, to cast one vote on each matter with respect to which shareholders have the right to vote, and to share ratably in all dividends and other distributions declared and paid with respect to common stock, as well as in the net assets of the corporation upon liquidation or dissolution.
In January 2022, the Company issued shares of common stock through the Private Placement for the purpose of raising capital. See Note 5 - Warrant Liabilities for proceeds received by the Company.
In January 2022, the Company issued shares of common stock pursuant to the Medigap Acquisition.
In
January 2022, upon agreement with Series A warrant holders, warrants were exercised at a price of $
In March 2022, the Company issued shares of the Company’s common stock due to the vesting of stock awards pursuant to an employee agreement.
In
May and June 2022,
As of June 30, 2022 and December 31, 2021, there were and shares of Common Stock outstanding, respectively.
Warrants
Series A warrant holders exercised Series A warrants in January 2022, resulting in of Series A warrants remaining issued and outstanding as of June 30, 2022.
| 17 |
In
January 2022, as a result of the issuance of common stock in the January 2022 stock offering and the Medigap Acquisition, the Company
received a deficiency notification from Nasdaq indicating violation of Listing Rule 5365(a). As part of its remediation plan, in March
2022, the Company entered into Exchange Agreements with the holders of common stock issued in January 2022. Pursuant to the Exchange
Agreements, the Company issued
In
May and June 2022, the
Equity-based Compensation
Between February and May 2022, three existing employees were awarded bonuses consisting of shares of the Company’s common stock to be vested immediately. The shares granted in 2022 were valued at $. For the three and six months ended June 30, 2022, compensation expense on these grants totaled $ and $, respectively. As of June 30, 2022, these shares have not been issued.
In
April 2022 , pursuant to an agreement between the Company and an Executive, the Executive will be compensated with
Basic EPS applicable to common stockholders is computed by dividing earnings applicable to common stockholders by the weighted-average number of common shares outstanding.
If there is a loss from operations, diluted EPS is computed in the same manner as basic EPS is computed. Similarly, if the Company has net income but its preferred dividend adjustment made in computing income available to common stockholders results in a net loss available to common stockholders, diluted EPS would be computed in the same manner as basic EPS.
SCHEDULE OF CALCULATIONS OF BASIC AND DILUTED EPS
| Three Months | Three Months | |||||||
| Ended | Ended | |||||||
| June 30, 2022 | June 30, 2021 | |||||||
| Net income (loss), numerator, basic and diluted computation | $ | $ | ( | ) | ||||
| Weighted average shares - denominator basic computation | ||||||||
| Effect of stock awards | ||||||||
| Effect of preferred stock | ||||||||
| Weighted average shares, as adjusted - denominator diluted computation | ||||||||
| Earnings (loss) per common share – basic | $ | $ | ( | ) | ||||
| Earnings (loss) per common share – diluted | ( | ) | ||||||
| Six Months | Six Months | |||||||
| Ended | Ended | |||||||
| June 30, 2022 | June 30, 2021 | |||||||
| Net income (loss) | $ | $ | ( | ) | ||||
| Deemed dividend | ( | ) | ||||||
| Net income (loss), numerator, basic computation | ( | ) | ||||||
| Recognition and change in fair value of warrant liability | ( | ) | ||||||
| Net income (loss), numerator, diluted computation | $ | ( | ) | $ | ( | ) | ||
| Weighted average shares - denominator basic computation | ||||||||
| Effect of Series B warrant liability | ||||||||
| Weighted average shares, as adjusted - denominator diluted computation | ||||||||
| Earnings (loss) per common share - basic | $ | $ | ( | ) | ||||
| Earnings (loss) per common share - diluted | $ | ( | ) | $ | ( | ) | ||
SCHEDULE OF ANTI-DILUTIVE SECURITIES IN WEIGHTED AVERAGE SHARES
| For the Three Months Ended | ||||||||
| June 30, 2022 | June 30, 2021 | |||||||
| Shares subject to outstanding common stock options | ||||||||
| Shares subject to outstanding Series A warrants | ||||||||
| Shares subject to unvested stock awards | ||||||||
| Shares subject to warrant liability | ||||||||
| For the six months ended | ||||||||
| June 30, 2022 | June 30, 2021 | |||||||
| Shares subject to outstanding common stock options | ||||||||
| Shares subject to outstanding Series A warrants | ||||||||
| Shares subject to conversion of Series B preferred stock | ||||||||
| Shares subject to unvested stock awards | ||||||||
| Weighted-average anti-dilutive securities | ||||||||
| 18 |
NOTE 8. LEASES
Operating
lease expense for the three months ended June 30, 2022 and 2021 was $
Future minimum lease payment under these operating leases consisted of the following:
SCHEDULE OF FUTURE MINIMUM LEASE PAYMENT
| Year ending December 31, | Operating Lease Obligations | |||
| 2022 | $ | |||
| 2023 | ||||
| 2024 | ||||
| 2025 | ||||
| 2026 | ||||
| Thereafter | ||||
| Total undiscounted operating lease payments | ||||
| Less: Imputed interest | ( | ) | ||
| Present value of operating lease liabilities | $ | |||
NOTE 9. COMMITMENTS AND CONTINGENCIES
Legal Contingencies
The Company is subject to various legal proceedings and claims, either asserted or unasserted, arising in the ordinary course of business. While the outcome of these claims cannot be predicted with certainty, management does not believe the outcome of any of these matters will have a material adverse effect on our business, financial position, results of operations, or cash flows, and accordingly, no legal contingencies are accrued as of June 30, 2022 and December 31, 2021. Litigation relating to the insurance brokerage industry is not uncommon. As such the Company, from time to time have been, subject to such litigation. No assurances can be given with respect to the extent or outcome of any such litigation in the future.
Earn-out liabilities
The following outlines changes to the Company’s earn-out liability balances inclusive of accumulated accretion for the respective period ended June 30, 2022 and December 31, 2021:
SCHEDULE OF EARN-OUT LIABILITY
| CCS | Fortman | Montana | Altruis | Kush | Barra | Total | ||||||||||||||||||||||
| Ending balance December 31, 2021 | $ | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||
| Changes due to acquisitions | ||||||||||||||||||||||||||||
| Changes due to payments | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||
| Changes due to fair value adjustments | ( | ) | ||||||||||||||||||||||||||
| Ending balance June 30, 2022 | $ | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||
| CCS | Fortman | Montana | Altruis | Kush | Total | |||||||||||||||||||
| Ending balance December 31, 2020 | $ | $ | $ | $ | $ | $ | ||||||||||||||||||
| Changes due to business combinations | ||||||||||||||||||||||||
| Changes due to payments | ( | ) | ( | ) | ||||||||||||||||||||
| Changes due to fair value adjustments | ( | ) | ( | ) | ( | ) | ||||||||||||||||||
| Changes due to write-offs | ( | ) | ( | ) | ||||||||||||||||||||
| Ending balance December 31, 2021 | $ | $ | $ | $ | $ | $ | ||||||||||||||||||
| 19 |
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), refers to controls and procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that such information is accumulated and communicated to a company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
The Company determined it had a material weakness in its disclosure controls and procedures as it pertains to earnings per share (EPS) for the three and six months ended June 30, 2022. During the quarter ended March 31, 2023, the Company mitigated this deficiency by consulting with qualified advisors that have in-depth EPS expertise. These advisors will assist the Company in the calculations and disclosures of EPS for future reporting periods. Pursuant to the above, our Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2022, concluding them to be ineffective as of such date.
Changes in Internal Control over Financial Reporting
There have not been any changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during our most recently completed fiscal quarter which is the subject of this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Item 6. Exhibits
The following exhibits are filed with this Form 10-K.
* Filed herewith.
** Furnished herewith.
| 20 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Reliance Global Group, Inc. | ||
| Date: May 18, 2023 | By: | /s/ Ezra Beyman |
| Ezra Beyman | ||
Chief Executive Officer (principal executive officer) | ||
| Date: May 18, 2023 | By: | /s/ Joel Markovits |
| Joel Markovits | ||
| Chief Financial Officer | ||
| (principal financial officer and principal accounting officer) |
| 21 |
Exhibit 31.1
CERTIFICATIONS
I, Ezra Beyman, certify that:
1. I have reviewed Amendment No. 1 to the Quarterly Report on Form 10-Q/A for the fiscal quarter ended June 30, 2022 of Reliance Global Group, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
| (a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly for the period in which this report is being prepared; | |
| (b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; | |
| (c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and | |
| (d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
| (a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and | |
| (b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
| Dated: May 18, 2023 | By: | /s/ Ezra Beyman |
| Ezra Beyman | ||
| Chief Executive Officer (Principal Executive Officer) |
Exhibit 31.2
CERTIFICATIONS
I, Joel Markovits, certify that:
1. I have reviewed Amendment No. 1 to the Quarterly Report on Form 10-Q/A for the fiscal quarter ended June 30, 2022 of Reliance Global Group, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
| (a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly for the period in which this report is being prepared; | |
| (b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; | |
| (c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and | |
| (d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):
| (a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and | |
| (b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
| Date: May 18, 2023 | By: | /s/ Joel Markovits |
| Joel Markovits | ||
| Chief Financial Officer (Principal Financial Officer) |
Exhibit 32.1
Certification
Pursuant to Section 906 of the Sarbanes-Oxley Act Of 2002
(Subsections (A) And (B) Of Section 1350, Chapter 63 of Title 18, United States Code)
Each of the undersigned officers of Reliance Global Group, Inc. (the “Company”), does hereby certify, that:
Amendment No. 1 to the Quarterly Report on Form 10-Q for the period ended June 30, 2022 (the “Form 10-Q/A”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q/A fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Date: May 18, 2023 | By: | /s/ Ezra Beyman |
| Ezra Beyman | ||
| Chief Executive Officer (Principal Executive Officer) | ||
| Date: May 18, 2023 | By: | /s/ Joel Markovits |
| Joel Markovits | ||
Chief Financial Officer (Principal Financial Officer) |